Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2025-12-26 @ 1:22 AM
Study NCT ID:
NCT04716933
Status:
COMPLETED
Last Update Posted:
2025-09-09
First Post:
2021-01-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-11-05
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-08-30
Completion Date Type:
ACTUAL
First Submit Date:
2021-01-19
First Submit QC Date:
None
Study First Post Date:
2021-01-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-07-30
Results First Submit QC Date:
None
Results First Post Date:
2024-10-04
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-20
Last Update Post Date:
2025-09-09
Last Update Post Date Type:
ESTIMATED